Zealand Pharma A/S. Overview
Latest PEG ratio for Zealand Pharma A/S.: -32.64 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-32.64
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for ZEAL is -32.64. That is below the Healthcare sector average of 2.89. Investors often review this figure alongside Zealand Pharma A/S.'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ZEAL currently prints -32.64 for PEG ratio, while the sector average sits near 2.89. That is roughly 1229.0% below the sector mean. Large gaps often invite a closer look at Zealand Pharma A/S.'s growth, margins, and balance sheet.
A PEG ratio of -32.64 for Zealand Pharma A/S. is not 'good' or 'bad' on its own. Compare it with the peer average (2.89) and with ZEAL's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ZEAL's PEG ratio (-32.64), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Zealand Pharma A/S.'s PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
